Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11971200 | 0.80 | PDE2A (0.59) | PDE2A | |
| SCHEMBL11971146 | 0.76 | PDE2A (0.64) | PDE2A | |
| SCHEMBL11971301 | 0.75 | ALDH1A1 (0.38) | PDE2AALDH1A1 | |
| SCHEMBL16210100 | 0.75 | BRD4 (0.46) | PDE2A | |
| SCHEMBL16210384 | 0.74 | PDE2A (0.38) | PDE2AALDH1A1 | |
| SCHEMBL11971379 | 0.74 | PDE2A (0.44) | PDE2A | |
| SCHEMBL16210056 | 0.73 | PDE10A (0.44) | PDE2A | |
| SCHEMBL11971560 | 0.73 | PDE2A (0.49) | PDE2A | |
| SCHEMBL11971375 | 0.73 | PDE2A (0.65) | PDE2A | |
| SCHEMBL18742167 | 0.71 | PDE2A (0.40) | PDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200000-B2 | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200000-B2 | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200000-B2 | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140066622-A1 | Imidazo[5,1-f][1,2,4]Triazines For The Treatment of Neurological Disorders | PFIZER INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066622-A1 | Imidazo[5,1-f][1,2,4]Triazines For The Treatment of Neurological Disorders | PFIZER INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066622-A1 | Imidazo[5,1-f][1,2,4]Triazines For The Treatment of Neurological Disorders | PFIZER INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8598155-B2 | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120214791-A1 | Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders | PFIZER INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120214791-A1 | Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders | PFIZER INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120214791-A1 | Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders | PFIZER INC. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066622-A1 | Imidazo[5,1-f][1,2,4]Triazines For The Treatment of Neurological Disorders | GRIK5, GRIN2C, BDNF | PDE2A 1800/4885ALDH1A1 545/4885 |
| US-20120214791-A1 | Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders | GRIK5, GRIN2C, BDNF | PDE2A 1800/4885ALDH1A1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.